The first ALS patient has been enrolled in an NIH-funded expanded access program trial evaluating MN-166 (ibudilast).

Brainstorm Cell Therapeutics is seeking FDA clearances to launch a Phase 3b clinical trial to test its NurOwn stem cell ...

Columnist Dagmar Munn explains how the use of a shoehorn not only helps her put on shoes, but also allows for some gentle ...

Neurosense Therapeutics’ PrimeC significantly reduces blood levels of miRNAs linked to amyotrophic lateral sclerosis, trial ...

Daily treatment with IPL344 for up to three years was safe and slowed ALS progression in a small Phase 2a clinical trial, ...

RAG-17 therapy slowed functional decline and stabilized or improved breathing in people with ALS who carry mutations in the SOD1 gene.